The US government is working with Bavarian Nordic A/S to help the company meet the demand for its monkeypox vaccine Jynneos, including looking at the potential of partnering with a “larger pharmaceutical company," as both national and global demand for the vaccine soars and the US government is under increasing pressure to better manage another health crisis.
The increasingly high demand and manufacturing need comes despite a US dose-sparing plan that allows for intradermal injection of smaller...